Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (2016 - 2026)

Ani Pharmaceuticals' Shares Outstanding history spans 16 years, with the latest figure at $23.1 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 9.5% to $23.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.1 million, a 9.5% increase, with the full-year FY2025 number at $23.1 million, up 9.5% from a year prior.
  • Shares Outstanding hit $23.1 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $23.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding for ANIP hit a ceiling of $23.1 million in Q4 2025 and a floor of $12.8 million in Q3 2021.
  • Historically, Shares Outstanding has averaged $19.1 million across 5 years, with a median of $20.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 45721.43% in 2021 and later increased 1.82% in 2024.
  • Tracing ANIP's Shares Outstanding over 5 years: stood at $16.9 million in 2021, then rose by 4.32% to $17.6 million in 2022, then increased by 17.5% to $20.7 million in 2023, then grew by 1.82% to $21.1 million in 2024, then rose by 9.5% to $23.1 million in 2025.
  • Business Quant data shows Shares Outstanding for ANIP at $23.1 million in Q4 2025, $23.1 million in Q3 2025, and $22.3 million in Q2 2025.